No Aprilov, it is not true. It is a complete misunderstanding of the differences between Phase I, II and III clinical trials. But if that is what they want to believe...
There is nothing that Pascoe stated or implied about going backwards with Femprox. The company is waiting for the FDA's decision on Flibanserin for a similar indication to see how the FDA rules before going forward with the design of a clinical trial, likely in conjunction with a partner. In fact, their updated presentation says they intend "Initiating (the Femprox) licensing process in early 2014."
Market Data 
Markets 
AI
